Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sepetaprost in Healthy Males
NCT05905653Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sepetaprost in Glaucoma and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: Maximum Plasma Concentration at Day 7. Started May 2023; status: completed.
02
Drugs
sepetaprost
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT05905653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905653.